Evidence map›Paper›PMID 32892316›Full record

Observational studyJournal of endocrinological investigation2021

A tool to predict survival in stage IV entero-pancreatic NEN.

M Tarquini, M R Ambrosio, M Albertelli, P B de Souza, R Gafà, I Gagliardi, A Carnevale, P Franceschetti, M C Zatelli

Abstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Journal of endocrinological investigation, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

M TarquiniDepartment of Medical Sciences, Section of Endocrinology and Internal Medicine, University of Ferrara, Via Ariosto 35, 44100, Ferrara, Italy.
M R AmbrosioDepartment of Medical Sciences, Section of Endocrinology and Internal Medicine, University of Ferrara, Via Ariosto 35, 44100, Ferrara, Italy.
M AlbertelliEndocrinology, Department of Internal Medicine DiMI, University of Genova, Genoa, Italy.
P B de SouzaDepartment of Medical Sciences, Section of Endocrinology and Internal Medicine, University of Ferrara, Via Ariosto 35, 44100, Ferrara, Italy.
R GafàPathology Unit, Department of Medical Sciences, University of Ferrara, Ferrara, Italy.
I GagliardiDepartment of Medical Sciences, Section of Endocrinology and Internal Medicine, University of Ferrara, Via Ariosto 35, 44100, Ferrara, Italy.
A CarnevaleDepartment of Morphology, Surgery and Experimental Medicine, University of Ferrara, Ferrara, Italy.
P FranceschettiEndocrine Unit, Azienda Ospedaliero-Universitaria di Ferrara, Via Aldo Moro 8, Cona, 44124, Ferrara, Italy.
M C ZatelliDepartment of Medical Sciences, Section of Endocrinology and Internal Medicine, University of Ferrara, Via Ariosto 35, 44100, Ferrara, Italy. ztlmch@unife.it.ORCID http://orcid.org/0000-0001-8408-7796

Funding

Ministero dell'Istruzione, dell'Università e della Ricerca PRIN 2017Z3N3YC
6 · The paper itself

Abstract

purposeWell-differentiated stage IV neuroendocrine neoplasms (NEN) have an extremely heterogeneous, unpredictable clinical behavior. Survival prognostic markers, such as the recently proposed NEP-Score, would be very useful for better defining therapeutic strategies. We aim to verify NEP-Score applicability in an independent cohort of stage IV well-differentiated (WD) gastroentero-pancreatic (GEP) NEN, and identify a derivate prognostic marker taking into account clinical and pathological characteristics at diagnosis.

methodsAge, site of primary tumor, primary tumor surgery, symptoms, Ki67, timing of metastases of 27 patients (10 females; mean age at diagnosis 60.2 ± 2.9 years) with stage IV WD GEP NEN were evaluated to calculate the NEP-Score at the end of follow-up (NEP-T). We calculated the NEP-Score at diagnosis (NEP-D), which does not consider the appearance of new metastases during follow-up. Patients were subdivided according to whether they were alive or not at the end of follow-up (EOF) and an NEP-Score threshold was investigated to predict survival.

resultsMean NEP-T and mean NEP-D were significantly lower in 15 live patients as compared to 12 deceased patients (p < 0.01) at EOF. We identified an NEP-D = 116 as the cutoff that significantly predicts survival. No gender differences were identified.

conclusionsIn our series, we confirmed NEP-Score applicability. In addition, we propose NEP-D as a simple, quick and cheap prognostic score that can help clinicians in decision making. NEP-D threshold can predict NEN aggressiveness and may be used to define the best personalized therapeutic strategy.

Indexed as

Digestive System Surgical ProceduresGastrointestinal NeoplasmsNeuroendocrine TumorsNomogramsPancreatic NeoplasmsBiomarkers, TumorFemaleHumansItalyKi-67 AntigenMaleMiddle AgedNeoplasm GradingNeoplasm MetastasisNeoplasm StagingPrognosisBiomarkers, TumorKi-67 AntigenMKI67 protein, humanNEP-DNEP-ScoreNEP-TNeuroendocrine neoplasmsSurvival

Identifiers

PMID32892316
PMCPMC8124053

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.